Mouse Anti Caenorhabditis elegans Perlecan Hybridoma [NI4]

Background: Juvederm Volux (VYC-25L; Allergan plc) is an injectable hyaluronic acid gel designed to restore and create facial volume. Objectives: The aim of this study was to evaluate the safety and effectiveness of Volux for chin retrusion over 18 months and after repeat treatment. Methods: This prospective, single-blind, controlled study enrolled subjects aged >= 18 years with chin retrusion (glabella-subnasale-pogonion facial angle 145 degrees-165 degrees). Subjects were randomized (3:1) to Volux at study onset or 3 months later (control group), and could receive a single repeat treatment during months 18 to 24. Assessments included mean facial-angle change from baseline, Global Aesthetic Improvement Scale (GAIS) responder rates (improved/much improved), improvements in 3 subject-reported FACE-Q scales, and safety. Results: Of 132 enrolled subjects, 119 received initial Volux treatment and 89 received repeat treatment. Mean changes (95% confidence interval) in glabella-subnasale-pogonion angle from baseline for treatment and control groups, respectively, were: 1.15 degrees (0.75 degrees, 1.56 degrees) and 1.16 degrees (0.57 degrees, 1.75 degrees) at month 18, and 3.14 degrees (2.68 degrees, 3.61 degrees) and 2.72 degrees (1.78 degrees, 3.66 degrees) 1 month after repeat treatment. Investigators rated 52.5%/60.0% of treated/control subjects at month 18 and 96.9%/100% after retreatment as GAIS responders; subject-reported rates were 62.0%/64.0% and 93.8%/100%. Durable improvements in Satisfaction with Chin, Satisfaction with Lower Face and Jawline, and Psychological Well-Being were reported in 82.1%, 78.2%, and 60.3% of subjects, respectively, at month 18, and 92.3%, 93.8%, and 67.7% of subjects after retreatment. The safety profile was as expected. Conclusions: Volux injectable gel is a safe, effective, and durable alternative to surgical treatments for increasing chin projection and jaw volume, and results in high patient satisfaction.

Herein, we develop a novel ultrasensitive and selective photoelectrochemical (PLC) immunosensor based on a potential-induced photocurrent-direction switching of the CdS-chitosan nanoparticles (CdS-CS NPs) and a direct Z-scheme CdS/hemin photocurrent-direction switching system. Taking the detection of Prion (PrPc) as example, the CdS-CS NPs served as photoactive materials showed a cathodic photocurrent by the potential-stimulated switching of the photocurrent direction strategy, after immobilization of the captured antibody of PrPc (Ab1) onto the surface of CdS-CS NPs, nitrogen-doped porous carbon (NPC)-hemin polyhedra labelled with secondary antibody of PrPc (Ab2) were subsequently introduced onto the immunosensing interface due to the antigen -antibody specific recognition, and could act as a photocurrent-direction converter of CdS-CS NPs to produce a big anodic photocurrent which was opposite to that of CdS-CS NPs, owe to the well-matched energy levels between CdS and hemin to form a direct Z-scheme CdS/hemin system. By coupling the potential-stimulated switching of the photocurrent direction strategy and direct Z-scheme photocurrent-direction switching system, PrPc was detected sensitively with a wide linear response range from 4 to 1000 aM and a low detection limit of 0.53 aM. Also, the developed PEC immunosensing platform showed excellent selectivity. Going beyond the conventional "signal-off" or "signal-on" driven immunosensor, this strategy may has promising applications in bioanalysis, disease diagnostics, and clinical biomedicine.